CME and CPD-accredited: Free, virtual event

Can you describe the additional benefits dPCR brings to standardized molecular testing of CML patients?

And you will too, after joining Prof. Susan Branford, SA Pathology, at our CME and CPD-accredited Global Oncohematology Summit, streaming live September 13– 14, where you’ll discover how opting for precision with dPCR can further improve CML patient management and outcomes.

Take the I Can pledge – a decision that improves patients’ lives – as Prof. Susan Branford discusses how standardization of molecular testing was achieved for patients with chronic myeloid leukemia (CML).
Sign me up!

She’ll illustrate how this model could be applied for other blood cancers and also address the importance of using the right tools for testing and monitoring patients. Real-time quantitative PCR has been a gold standard for quantitative assessment of BCR::ABL1 levels, but digital PCR could provide additional benefits for the precise assessment of measurable residual disease.

 

“Educational programs such as this one are important because they communicate knowledge and ideas that could ultimately improve patient management and outcomes.”

Prof. Susan Branford SA Pathology

In addition to Prof. Branford’s presentation, we’ve organized a great lineup of speakers specializing in different blood cancer malignancies. Be sure to take a look at the full, two-day agenda.

 
Reserve your space

We can’t wait to see you there!

Kind regards,

Your QIAGEN Oncohematology team
Sample to Insight